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Discussion
Dr Vaughn A. Starnes (Los Angeles, Calif). We know that
Euro-Collins solution can tend to be vasoconstrictive, and that is
the reason we started using prostacyclin way back when. Do you
have a group there in which you compared prostacyclin/Euro-
Collins with PER?
Dr Albes. Yes. In this particular model we added prostacyclin
to our Euro-Collins solution and compared it with both PER
groups.
Dr Thomas K. Waddell (Toronto, Ontario, Canada). I con-
gratulate you on your study. I think I generally believe the results,
but I would like to comment about some other potential control
groups that you might have included. Obviously nitroglycerin is a
vasodilator, and therefore you might consider, and I think you
suggested it yourself, that the flush time is shorter and, in fact, the
flush efficiency might be greater in the presence of a vasodilator.
Not to say that nitroglycerin is bad, but it might not be working
entirely through the NO pathway. Also, NO has other effects that
are mediated not through cyclic guanosine monophosphate
(cGMP). Therefore, you could try other ways of targeting both the
cGMP pathway and the non-cGMP pathway downstream of NO to
determine what exactly is responsible for the mechanism of ben-
efit.
Dr Albes. Thank you for this comment. It is certainly clear that
we can investigate much more. We intend to perform a large-
animal study to verify these initial findings, especially regarding
NO’s effects on the microvasculature.
Dr Irving L. Kron (Charlottesville, Va). I have one question.
NO has two faces, as you well know. Let us assume that it has the
effects you think it does. If you give it to a lung that is not having
any difficulty, it would work perfectly. But let us say injury has
already occurred, and many of us believe reperfusion injury is part
of the neurogenic pulmonary edema and that we just caught it at
the wrong time. Could it potentially have a deleterious effect in
that situation?
Dr Albes. NO surely has two faces because it is still a free
radical. Deleterious effects might therefore occur. However, those
were not observed by us. Unfortunately, it has always been a
problem in a small-animal experimental study to investigate many
details. We therefore had to remain concise and focus on just a few
aspects in our laboratory work.
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